Bloomberg Businessweek ICYMI: Eli Lilly's New Weight Loss Pill
Apr 21, 2025
Damian Garde, Bloomberg News healthcare reporter, discusses Eli Lilly's promising new weight loss pill that's shaking up the market. The conversation reveals how this pill could rival the popular Ozempic, as it potentially offers a more convenient option. Garde explores the competitive landscape among pharmaceutical giants striving for a piece of the predicted $130 billion market. He also sheds light on the contrasting fortunes of Eli Lilly and UnitedHealth, highlighting the ongoing challenges in the healthcare industry.
AI Snips
Chapters
Transcript
Episode notes
Lilly's Oral Pill Rival to Ozempic
- Eli Lilly's experimental weight loss pill works as well as Novo Nordisk's Ozempic injection for type 2 diabetes patients.
- This pill could become the easier-to-take, needle-free alternative that revolutionizes obesity and diabetes treatment.
Side Effects May Limit Adoption
- Side effects from weight loss drugs mostly involve gastrointestinal issues like nausea and diarrhea.
- These side effects could be the main barrier for patients, rather than needle aversion.
Lilly Outgamming Novo Nordisk
- Lilly and Novo Nordisk have competed in diabetes treatment for over a century.
- Lilly is currently leading by developing a better injectable and now an oral pill, challenging Novo's dominance.